How do you initiate and monitor micro‑dose ketamine therapy in an adult patient with treatment‑resistant depression?

Ketamine for Treatment-Resistant Depression: Initiation and Monitoring Protocol

Reserve ketamine therapy exclusively for patients with treatment-resistant depression who have failed at least 2 adequate trials of antidepressant medications, and administer it via intravenous infusion at 0.5 mg/kg over 40 minutes in a monitored clinical setting with mandatory post-treatment observation. 1

Patient Selection Criteria

Who Qualifies

• Adults with major depressive disorder who have documented failure of at least 2 adequate antidepressant trials (minimum effective dose for ≥4 weeks each, different mechanisms of action) 1
• Patients with treatment-resistant depression (TRD) with or without acute suicidal ideation 1
• Can be used as monotherapy or adjunctive to ongoing antidepressant treatment 1

Who Should NOT Receive Ketamine

• Patients who have not tried standard first-line treatments 1
• Those with uncontrolled hypertension or cardiovascular instability 2
• Patients with elevated intracranial pressure 2
• Active substance use disorder (not in remission) 3
• Concurrent use of theophylline or aminophylline (lowers seizure threshold) 2

Pre-Treatment Requirements

Baseline Assessment

Obtain these specific tests before initiating treatment:

• Liver function tests (alkaline phosphatase, gamma-glutamyl transferase, AST, ALT) 2
• Blood pressure and cardiovascular assessment 2
• Psychiatric evaluation documenting previous treatment failures 3
• Screening for substance use history 2

Infrastructure Requirements

• Certified healthcare setting with monitoring capabilities 1
• Equipment for vital sign monitoring (BP, pulse oximetry, respiratory rate) 2
• Emergency resuscitation equipment available 2
• Private treatment space to minimize stimulation during emergence 2

Dosing Protocol

Standard IV Ketamine Regimen

Initial Treatment Phase:

• Dose: 0.5 mg/kg IV infusion over 40 minutes 1
• Frequency: Twice weekly for 2-4 weeks (typically 4-6 total infusions) 1
• Route: Intravenous infusion only for initial treatment 1

The evidence strongly supports IV administration over other routes for initial treatment. While oral ketamine has been studied 4, 5, the 2022 VA/DoD guidelines specifically recommend IV ketamine infusion based on the strongest evidence 1.

Alternative Dosing Considerations

If IV access is problematic or for maintenance therapy, some centers use:

• Intramuscular: Can be used as test of responsiveness 6
• Oral: 2.0-2.5 mg/kg (to account for 20-25% bioavailability) 4
• Sublingual troches: Emerging data but limited evidence 7

However, these alternative routes lack the robust evidence base of IV administration and should be considered only after consultation with specialists experienced in ketamine therapy.

Monitoring During Treatment

Immediate Monitoring (During Infusion)

• Continuous vital signs: Blood pressure, heart rate, respiratory rate, oxygen saturation 2
• Neurological status: Level of consciousness, emergence reactions 2
• Dissociative symptoms: Expected but monitor intensity 2

Post-Infusion Monitoring

Mandatory 2-hour observation period (similar to esketamine REMS requirements) 1

• Vital signs every 15-30 minutes initially
• Assess for emergence reactions (hallucinations, agitation, confusion) 2
• Ensure patient is stable before discharge
• Patient must have escort home; cannot drive 2

Ongoing Monitoring (Throughout Treatment Course)

• Liver function tests: Repeat at periodic intervals during recurrent dosing 2
• Depression scales: MADRS or QIDS-SR at each visit 3
• Suicidal ideation: Specific assessment at 24 hours and subsequent visits 8
• Urinary symptoms: Screen for dysuria, frequency, urgency (associated with chronic use) 2

Expected Response Timeline

Acute Effects

• 24 hours: Significant improvement in depressive symptoms expected 1
• 3-7 days: Benefits persist when used adjunctively with ongoing antidepressants 1
• Suicidal ideation: May improve within 40-240 minutes 8

Duration of Benefit

• Monotherapy: Effects typically diminish by 7 days 1
• Adjunctive therapy: Benefits may extend up to 7 days 1
• Maintenance: Requires ongoing treatment strategy (see below)

Maintenance Strategy

The evidence for long-term ketamine use is limited. 1 After acute response:

1. Continue or optimize oral antidepressant if ketamine was used adjunctively 1
2. Consider transition to esketamine if longer-term maintenance data is needed 1
3. Repeat infusions: Some protocols use once-weekly maintenance, but this is not well-established 1
4. Monitor for hepatobiliary dysfunction with recurrent use 2

Critical Safety Warnings

Emergence Reactions

• Occur in up to 50% of patients 2
• Manifest as vivid dreams, hallucinations, delirium, confusion 2
• Mitigation: Minimize external stimulation, quiet environment, reassurance 2
• Consider benzodiazepine premedication in high-risk patients (though this may reduce efficacy) 2

Cardiovascular Effects

• Hypertension and tachycardia are common 2
• Enhanced by concurrent sympathomimetics or vasopressin 2
• Monitor closely; may require dose adjustment or antihypertensive intervention 2

Respiratory Depression

• Risk increased with concurrent opioids, benzodiazepines, or CNS depressants 2
• Have reversal agents available
• Continuous pulse oximetry mandatory 2

Hepatobiliary Dysfunction

• Cholestatic pattern with recurrent use 2
• Biliary duct dilatation reported 2
• Baseline and periodic LFTs are mandatory 2

Abuse Potential

• Ketamine is a controlled substance with abuse potential 2
• Screen for substance use history
• Document medical necessity
• Consider psychiatric consultation for patients with addiction history 2

Common Pitfalls to Avoid

1. Using ketamine as first-line treatment: This contradicts guidelines and wastes a potentially valuable option 1

2. Inadequate monitoring: The 2-hour post-treatment observation is not optional 1

3. Ignoring liver function: Recurrent dosing without LFT monitoring risks serious hepatobiliary complications 2

4. Allowing patients to drive home: Dissociative effects and cognitive impairment persist post-treatment 2

5. Failing to document previous treatment failures: Proper documentation of ≥2 adequate antidepressant trials is essential for justifying ketamine use 1, 3

6. Using oral/sublingual routes without IV trial first: The evidence base strongly favors IV administration initially 1

7. Continuing indefinitely without reassessment: Long-term safety data is lacking; regular reassessment of risk-benefit is essential 1

Drug Interactions Requiring Dose Adjustment

• Theophylline/aminophylline: Consider alternative to ketamine 2
• Sympathomimetics/vasopressin: Close vital sign monitoring, individualized dosing 2
• Benzodiazepines/opioids/CNS depressants: Profound sedation risk; reduce doses of both agents 2

Documentation Requirements

For each treatment session, document:

• Pre-treatment vital signs and mental status
• Exact dose and infusion time
• Vital signs during and post-infusion
• Emergence reactions or adverse effects
• Time patient deemed stable for discharge
• Escort confirmed present

1, 2